http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H01301619-A

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0931241d9441d023245580a92141bf68
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-405
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-195
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P3-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-415
filingDate 1988-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e187489366479edbed95886c08c89d2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_49554db8ecb1408904e486d020d7b1b7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0e14d233e974946b0464e273881bf62d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_af45e220869eb512eee7d4336a9b0391
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bdd102aeb69d4f34c3cd541c653d19a6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2102a8a2493df25f785d35a93c2686d3
publicationDate 1989-12-05-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-H01301619-A
titleOfInvention Amino acid pharmaceutical for cancer
abstract PURPOSE: To obtain an amino acid pharmaceutical, containing prescribed amino acids, having a free amino acid composition within specific range, serving both as cancer treatment and as nutriment supply and capable of rapidly improving immunological competence without side effects, such as intoxication symptoms or fatty liver. n CONSTITUTION: An amino acid, having a composition converted into free amino acids shown in the table with the content of branched chain amino acids consisting of preferably L-leucine, L-isoleucine and L-valine of ≥20wt.%, especially 20-30wt.% based on the total amino acids and ≥3.0, especially 4.0-7.0 weight ratio of essential amino acids to nonessential amino acids except L- arginine. The above-mentioned pharmaceutical is capable of causing an ideal state of amino acid imbalance in tumorous cells, normalizing amino acid values in blood of patients suffering from cancer, suppressing propagation of tumors and supplying body proteins and improving nutrient state and immunological competence. The pharmaceutical is preferably prepared in the form of an amino acid transfusion solution in 10.0-14.0wt./vol.% amino acid concentration and pH 4.0-7.5 and administered in a dose of 200-1,000ml/day for an adult. n COPYRIGHT: (C)1989,JPO&Japio
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2008050836-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2010506883-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2004026294-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5767091-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011021926-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011021938-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-03030890-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H06256184-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013100336-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2006213688-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-685585-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2020536096-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011021938-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0925726-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006070874-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9522967-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2135604-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2135604-A4
priorityDate 1988-05-30-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5351546
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399947
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID232
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6322
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419549088
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6106
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6287
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419537902
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395986
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6306
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID451398892
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226394420
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9907842
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419490523
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226410640
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419558427

Total number of triples: 56.